Targeting AXL can effectively overcome c-Met-induced therapeutic resistance in renal cancer and promote tumor cell death through increased oxidative stress
- 18 August 2025
- journal article
- Published by Elsevier in Cancer Letters
- Vol. 633, 217984
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (R01CA262577)
- US Department of Defense (W81XWH-21-1-0339)
- US Department of Defense (W81XWH-21-1-0234)
- US Department of Defense (W81XWH-19-1-0554)
- Deutsche Forschungsgemeinschaft (404527522)
- Dana-Farber Cancer Institute
- Dana Foundation
- Harvard Medical School
- American Society of Nephrology
- Else Kröner-Fresenius-Stiftung
- National Cancer Coalition
- Medical Research Foundation
- Exelixis
- National Institutes of Health National Cancer Institute (5P30CA006516-56)
- National Institutes of Health National Cancer Institute (R03CA230944)
- National Institutes of Health National Cancer Institute (R01CA251555)
This publication has 89 references indexed in Scilit:
- SIK1 promotes ferroptosis resistance in pancreatic cancer via HDAC5-STAT6-SLC7A11 axisCancer Letters, 2025
- Cancer resistance and metastasis are maintained through oxidative phosphorylationCancer Letters, 2024
- Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancerESMO Open, 2021
- The c-MET oncoprotein: Function, mechanisms of degradation and its targeting by novel anti-cancer agentsBiochimica et Biophysica Acta (BBA) - General Subjects, 2020
- Isolation of Tumor-Infiltrating Lymphocytes by Ficoll-Paque Density Gradient Centrifugation2019
- Disproportionately high levels of HGF induce the degradation of the c-met receptor through the proteasomal degradation pathwayBiochemical and Biophysical Research Communications, 2018
- Tumor Drug Penetration Measurements Could Be the Neglected Piece of the Personalized Cancer Treatment PuzzleClinical Pharmacology & Therapeutics, 2018
- Population exposure–response analysis of cabozantinib efficacy and safety endpoints in patients with renal cell carcinomaCancer Chemotherapy and Pharmacology, 2018
- Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-Small Cell Lung Cancer Associated With Poor PrognosisEBioMedicine, 2018
- Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemiaCancer Letters, 2008